Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
- Autores
- Pérez Lloret, Santiago; Cardinali, Daniel Pedro
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Fil: Pérez Lloret, Santiago. Universidad Abierta Interamericana. Centro de Altos Estudios en Ciencias Humanas y de la Salud; Argentina
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina
Abstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2–5mg/ day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75%of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset. Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40–100 mg/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect. - Fuente
- Frontiers in pharmacology Vol.12, Art.650597, 2021
- Materia
-
MELATONINA
ENFERMEDAD DE PARKINSON
ENVEJECIMIENTO
NEURODEGENERACION
ENFERMEDADES NEURODEGENERATIVAS
TRATAMIENTO MEDICO - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/4.0/
- Repositorio
- Institución
- Pontificia Universidad Católica Argentina
- OAI Identificador
- oai:ucacris:123456789/11620
Ver los metadatos del registro completo
id |
RIUCA_e138e2c70d957fd3769236b4a804afc8 |
---|---|
oai_identifier_str |
oai:ucacris:123456789/11620 |
network_acronym_str |
RIUCA |
repository_id_str |
2585 |
network_name_str |
Repositorio Institucional (UCA) |
spelling |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s diseasePérez Lloret, SantiagoCardinali, Daniel PedroMELATONINAENFERMEDAD DE PARKINSONENVEJECIMIENTONEURODEGENERACIONENFERMEDADES NEURODEGENERATIVASTRATAMIENTO MEDICOFil: Pérez Lloret, Santiago. Universidad Abierta Interamericana. Centro de Altos Estudios en Ciencias Humanas y de la Salud; ArgentinaFil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; ArgentinaFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; ArgentinaAbstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2–5mg/ day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75%of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset. Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40–100 mg/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect.Frontiers Media2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/116201663-981210.3389/fphar.2021.65059733935759Pérez Lloret, S., Cardinali, D. P. Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease [en línea]. Frontiers in pharmacology. 2021, 12 (650597). doi:10.3389/fphar.2021.650597. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11620Frontiers in pharmacology Vol.12, Art.650597, 2021reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:57:51Zoai:ucacris:123456789/11620instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:57:51.664Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse |
dc.title.none.fl_str_mv |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
title |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
spellingShingle |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease Pérez Lloret, Santiago MELATONINA ENFERMEDAD DE PARKINSON ENVEJECIMIENTO NEURODEGENERACION ENFERMEDADES NEURODEGENERATIVAS TRATAMIENTO MEDICO |
title_short |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
title_full |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
title_fullStr |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
title_full_unstemmed |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
title_sort |
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease |
dc.creator.none.fl_str_mv |
Pérez Lloret, Santiago Cardinali, Daniel Pedro |
author |
Pérez Lloret, Santiago |
author_facet |
Pérez Lloret, Santiago Cardinali, Daniel Pedro |
author_role |
author |
author2 |
Cardinali, Daniel Pedro |
author2_role |
author |
dc.subject.none.fl_str_mv |
MELATONINA ENFERMEDAD DE PARKINSON ENVEJECIMIENTO NEURODEGENERACION ENFERMEDADES NEURODEGENERATIVAS TRATAMIENTO MEDICO |
topic |
MELATONINA ENFERMEDAD DE PARKINSON ENVEJECIMIENTO NEURODEGENERACION ENFERMEDADES NEURODEGENERATIVAS TRATAMIENTO MEDICO |
dc.description.none.fl_txt_mv |
Fil: Pérez Lloret, Santiago. Universidad Abierta Interamericana. Centro de Altos Estudios en Ciencias Humanas y de la Salud; Argentina Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina Abstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2–5mg/ day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75%of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset. Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40–100 mg/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect. |
description |
Fil: Pérez Lloret, Santiago. Universidad Abierta Interamericana. Centro de Altos Estudios en Ciencias Humanas y de la Salud; Argentina |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://repositorio.uca.edu.ar/handle/123456789/11620 1663-9812 10.3389/fphar.2021.650597 33935759 Pérez Lloret, S., Cardinali, D. P. Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease [en línea]. Frontiers in pharmacology. 2021, 12 (650597). doi:10.3389/fphar.2021.650597. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11620 |
url |
https://repositorio.uca.edu.ar/handle/123456789/11620 |
identifier_str_mv |
1663-9812 10.3389/fphar.2021.650597 33935759 Pérez Lloret, S., Cardinali, D. P. Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease [en línea]. Frontiers in pharmacology. 2021, 12 (650597). doi:10.3389/fphar.2021.650597. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11620 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/4.0/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers Media |
publisher.none.fl_str_mv |
Frontiers Media |
dc.source.none.fl_str_mv |
Frontiers in pharmacology Vol.12, Art.650597, 2021 reponame:Repositorio Institucional (UCA) instname:Pontificia Universidad Católica Argentina |
reponame_str |
Repositorio Institucional (UCA) |
collection |
Repositorio Institucional (UCA) |
instname_str |
Pontificia Universidad Católica Argentina |
repository.name.fl_str_mv |
Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina |
repository.mail.fl_str_mv |
claudia_fernandez@uca.edu.ar |
_version_ |
1836638355570294784 |
score |
13.13397 |